Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
News about Predictmedix AI Inc. (PMEDF) centers on its development of AI-powered health and safety technology, rapid health screening, and remote patient care platforms. Company announcements describe SmartHealth AI stations and Safe Entry Stations that use proprietary artificial intelligence and multispectral cameras to analyze physiological data patterns, predict vital parameters, and assess issues such as impairment, fatigue, and certain mental illnesses.
Recent releases highlight a multi-vertical growth strategy built around a single Core AI Engine. News items cover the launch of a Clinical-Trial AI Platform designed to simulate and optimize clinical trials, including features like adaptive simulations, patient-site optimization, cost and ROI modeling, and compliance-integrated AI. Other updates describe expansion into consumer digital health through a mobile diabetes screening platform that uses AI-driven facial and biometric analysis via smartphone for non-invasive diabetic risk scoring.
Investors and observers can also find coverage of Predictmedix AI’s capital markets activity, including non-brokered private placements, insider participation, and the stated use of proceeds to advance its AI engine, SmartHealth AI Station certification initiatives, clinical-trial applications, and B2C mobile platforms. Additional news includes participation in international investor conferences and roadshows, as well as selection for a Canadian government trade mission to Mexico to explore commercial opportunities for its health and safety technologies.
Together, these news items provide insight into how Predictmedix AI positions itself at the intersection of AI, quantum-inspired computation, and healthcare, and how it is communicating its technology roadmap, financing plans, and international engagement to the market.
QScreen AI (OTC Pink: PMEDF) announced a non‑brokered private placement to issue up to 10,000,000 units at C$0.05 per Unit for aggregate gross proceeds of up to C$500,000. Each Unit includes one common share and one half warrant; each warrant allows purchase of one half share at C$0.15 for 36 months.
Proceeds will fund structured pilot discussions, operational integration planning and working capital to scale commercialization across healthcare, industrial and technology sectors, building on recent trade mission activity in Mexico.
QScreen AI (OTC: PMEDF) reported substantive commercialization discussions during the Government of Canada trade mission to Mexico on February 23, 2026. The company held structured one-on-one meetings across healthcare, defense, advanced manufacturing, agri-food, infrastructure, and AI ecosystems.
Discussions advanced to defined follow-up talks to shape pilot scope, deployment parameters, and integration requirements; definitive agreements remain subject to customary commercial evaluation and approvals. The company noted a recent U.S. patent filing and said Mexico represents a sizable addressable opportunity for enterprise-scale Quantum-AI screening solutions.
QScreen AI (OTC Pink: PMEDF) filed a U.S. provisional patent (Application 63/981,576) for a "Quantum-Inspired Multi-Objective Optimization" platform aimed at clinical intake and readiness workflows.
The filing, highlighted during national CBC coverage, emphasizes solver-agnostic quantum-inspired algorithms, robotic deployments, surge-responsive controls, and commercial focus on defense, public safety, and enterprise screening.
QScreen AI (OTC Pink: PMEDF) announced an independent contractor agreement with Global Frontier Advisors L.P., effective January 30, 2026. The engagement will use equity and performance-based compensation, pending regulatory and exchange approvals.
The mandate targets commercialization and business development across correctional, institutional, industrial, defense, and large-event public-safety settings, led by managing partner Lieutenant General Michael S. Groen (Ret.), aiming to expand QScreen AI's U.S. and international presence for preemptive health surveillance and workplace safety.
QScreen AI Inc. (OTC: PMEDF; CSE: QAI) completed a formal name change from Predictmedix AI to QScreen AI effective on or about January 27, 2026. The change does not affect share capital, business operations, management, or strategic direction.
The company issued a new CUSIP 746960103 and ISIN CA7469601032, and expects Common Shares to trade under the new CSE symbol QAI at market open. QScreen AI says it is evolving from single-application screening to a broader decision-intelligence platform that integrates quantum-inspired and advanced computational techniques with classical machine learning to improve detection, speed, and scalability and to support commercialization across healthcare, safety, and adjacent markets.
Predictmedix (OTC: PMEDF) was selected for the Official Canada Trade Mission to Mexico, Feb 15–20, 2026, led by Minister Dominic LeBlanc. The company gains government‑facilitated introductions to Mexican distributors, clients, and industry leaders across Mexico City, Guadalajara, and Monterrey to accelerate market entry and revenue opportunities.
Predictmedix will access sector briefings, strategic site visits, and concierge support from the Trade Commissioner Service, while highlighting quantum‑inspired algorithm integration and plans to onboard regional distribution leadership to drive LATAM commercialization.
Predictmedix AI (OTC: PMEDF) announced a proposed name change to QScreen AI Inc. with a planned ticker QAI, subject to regulatory approval. The rebrand reflects a strategic shift toward combining artificial intelligence with quantum-inspired computing to improve preventive screening, diagnostics and personalized care. The company reports a proprietary dataset of over 720,000 scans collected via SmartHealth AI Stations and describes hybrid quantum-classical models that run on standard hardware. Management said the move supports commercialization, strategic hires, and global market penetration, with updates to shareholders provided as approvals progress.
Predictmedix AI (OTC: PMEDF; CSE: PMED) closed 2025 highlighting technology progress, global investor outreach, and commercial validation across its AI-driven health screening platform.
Key 2025 milestones: 500,000 real-world scans via SmartHealth AI Stations, deployment of hybrid quantum-classical algorithms that run on standard hardware to improve noise reduction and detection clarity, a targeted European investor roadshow, and a plan to issue 12.3 million common shares to nine consultants to align contributors with long-term goals.
The company plans to scale deployments, expand mobile solutions, accelerate commercialization, and further integrate quantum-inspired computation in 2026.
Predictmedix AI (OTC: PMEDF) closed the final tranche of a non-brokered private placement on December 5, 2025, issuing 3,050,000 Units at C$0.05 each for gross proceeds of $152,500, bringing total capital raised across all tranches to $612,650.
Each Unit includes one common share and one half warrant; each full Warrant allows purchase of one common share at C$0.15 for 36 months. Warrants may be accelerated if the CSE volume-weighted average share price equals or exceeds C$0.30 for 10 consecutive trading days after the four-month hold.
All securities are subject to a statutory hold of four months and one day. Management described the raise as selective and strategic, focused on investors who add operational value rather than maximizing capital.
Predictmedix AI (OTC: PMEDF) announced the closing of the first tranche of a non-brokered private placement on November 17, 2025. The company issued 9,203,000 Units at C$0.05 per Unit, raising gross proceeds of $460,150. Each Unit includes one common share and one half warrant; each full Warrant allows purchase of one common share at C$0.15 and expires in 36 months. The warrant expiry may be accelerated if the 10-day VWAP reaches $0.30 after the four-month hold period. Insiders subscribed $60,000 of the tranche, and all securities are subject to a statutory hold of four months and one day.
Predictmedix said the financing follows recent European investor outreach, including participation at the 25th MK Investment Conference in Munich.